<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="448">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155319</url>
  </required_header>
  <id_info>
    <org_study_id>EBS-UFV-001</org_study_id>
    <nct_id>NCT05155319</nct_id>
  </id_info>
  <brief_title>Phase 1 Universal Influenza A Vaccine in Healthy Adults</brief_title>
  <acronym>EBS-UFV-001</acronym>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study Evaluating Safety and Immunogenicity of Influenza A Hemagglutinin Stabilized Stem Nanoparticle Vaccine Candidate in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this Phase 1, single- center, randomized, double blind, placebo-controlled&#xD;
      dose-escalation study is to evaluate the safety, tolerability and immunogenicity of UFluA&#xD;
      vaccine candidate at two dose levels and two schedules in healthy adult (18-45-year-old,&#xD;
      inclusive) male and non-pregnant female subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 60 healthy adult subjects will be enrolled in the study and followed through Day&#xD;
      337 (i.e., up to 48 weeks after first dose). Subjects will be enrolled into two study cohorts&#xD;
      to receive either a low dose (Cohort 1; n=30 receives) or high dose (Cohort 2; n=30) of&#xD;
      adjuvanted UFluA or placebo (saline), administered intramuscularly (IM) as single dose or as&#xD;
      two doses (administered 21 days apart).&#xD;
&#xD;
      UFluA is comprised of DP-UFluA (1:1 A1-ssnp and A2-ssnp antigens) and contains aluminum&#xD;
      hydroxide and CpG adjuvants.&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To evaluate safety and tolerability of UFluA IM administration in healthy adults.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To assess anti-hemagglutinin humoral immune responses in healthy adults who receive UFluA. To&#xD;
      assess ferritin (Helicobacter pylori and human) immune response in healthy adults who receive&#xD;
      UFluA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint 1</measure>
    <time_frame>48 weeks</time_frame>
    <description>Incidence of SAEs up to 48 weeks of study follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Endpoint 2</measure>
    <time_frame>4 weeks after last dose</time_frame>
    <description>Incidence of AEs up to four weeks after last dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Endpoint 3</measure>
    <time_frame>seven days after each vaccination</time_frame>
    <description>Incidences of local reactogenicity events up to seven days after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Endpoint 4</measure>
    <time_frame>seven days after each vaccination</time_frame>
    <description>Incidences of systemic reactogenicity events up to seven days after each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Endpoint 5</measure>
    <time_frame>Up to 48 weeks of study follow up</time_frame>
    <description>Incidence of adverse events of special interest (AESIs) up to 48 weeks of study follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Endpoint 6</measure>
    <time_frame>Up to 48 weeks of study follow up</time_frame>
    <description>Incidence of medically attended adverse events (MAAEs) up to 48 weeks of study follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint 1</measure>
    <time_frame>four weeks after the last dose.</time_frame>
    <description>Proportion of subjects with positive H. pylori ferritin antibody after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint 2</measure>
    <time_frame>four weeks after the last dose.</time_frame>
    <description>Proportion of subjects with human ferritin antibody levels outside of an established normal human range after vaccination four weeks after the last dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint 3</measure>
    <time_frame>four weeks after the last dose.</time_frame>
    <description>Anti-hemagglutinin antibody response elicited by A1-ssnp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint 4</measure>
    <time_frame>four weeks after the last dose.</time_frame>
    <description>Anti-hemagglutinin antibody response elicited by A2-ssnp.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Human Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort 1, 1A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Dose/Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, 1B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Dose/Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1, 1C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, 2A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose/Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, 2B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose/High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, 2C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UFluA 20 µg each antigen/dose</intervention_name>
    <description>Low dose (Day 1) plus placebo (Day 22)</description>
    <arm_group_label>Cohort 1, 1A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UFluA 20 µg each antigen/dose</intervention_name>
    <description>Low dose (Day 1) plus low dose (Day 22)</description>
    <arm_group_label>Cohort 1, 1B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UFluA 60 µg each antigen/dose</intervention_name>
    <description>High dose (Day 1) plus placebo (Day 22)</description>
    <arm_group_label>Cohort 2, 2A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UFluA 60 µg each antigen/dose</intervention_name>
    <description>High dose (Day 1) plus high dose (Day 22)</description>
    <arm_group_label>Cohort 2, 2B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort 1, 1C</arm_group_label>
    <arm_group_label>Cohort 2, 2C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female adults (18-45 years of age, inclusive) at the Screening visit.&#xD;
&#xD;
          -  Body mass index of 18.5-&lt;30.0 kg/m2 at the Screening visit.&#xD;
&#xD;
          -  Healthy, based on medical history (no chronic disease, no chronic therapy, no ongoing&#xD;
             acute condition within four weeks prior to dosing), normal PE (no clinically&#xD;
             significant f findings in the opinion of the PI [or designee]), normal ECG based on&#xD;
             PI's (or designee's) review of screening tracing results and screening laboratory&#xD;
             assessments(no clinically significant findings in the opinion of the PI [or&#xD;
             designee]).&#xD;
&#xD;
          -  Females must not be pregnant or trying to become pregnant.&#xD;
&#xD;
          -  Both male and female subjects agree to acceptable forms of birth control. Male&#xD;
             subjects must not donate sperm for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrollment in an interventional study and/or receipt of any investigational product&#xD;
             within 30 days prior to screening visit or during the study.&#xD;
&#xD;
          -  Currently breastfeeding or planning to be breastfeeding during the study.&#xD;
&#xD;
          -  History of severe allergic reaction(s) or anaphylaxis.&#xD;
&#xD;
          -  Known allergy to any component of the vaccine.&#xD;
&#xD;
          -  History of any known immunodeficiency or immunocompromising condition that could&#xD;
             impact response to administration of the investigational product (e.g., leukemia,&#xD;
             lymphoma, malignancy, renal failure, asplenia, diabetes mellitus, alcoholic&#xD;
             cirrhosis).&#xD;
&#xD;
          -  Receipt or anticipated receipt of blood products from 180 days prior to the Screening&#xD;
             visit through 90 days following administration of IP.&#xD;
&#xD;
          -  Positive laboratory evidence of current infection at the Screening visit with HIV 1&#xD;
             and 2 (as determined by HIV 1/2 antibody test), HCV (as determined by HCV antibody&#xD;
             test), or HBV [as determined by HBV surface antigen (HBsAg) test]. Note: positive&#xD;
             anti-HCV antibody result along with a negative HCV PCR result would not be&#xD;
             exclusionary.&#xD;
&#xD;
          -  An abnormal ECG based on the PI's (or designee's) review of tracing results at the&#xD;
             Screening visit. [Non-pathologic sinus bradycardia (heart rate must be &gt;40 beats per&#xD;
             minute) is allowed].&#xD;
&#xD;
          -  Receipt or anticipated receipt of the seasonal influenza vaccination from up to 90&#xD;
             days prior to dosing and through up to 30 days following the last dose administration.&#xD;
&#xD;
          -  Receipt or anticipated receipt of any COVID-19 vaccine from up to 14 days prior to&#xD;
             dosing and through up to 30 days following the last dose administration.&#xD;
&#xD;
          -  Receipt or anticipated receipt of any other vaccines from up to 90 days prior to&#xD;
             dosing and through up to 30 days following last dose administration of investigational&#xD;
             product.&#xD;
&#xD;
          -  Receipt or anticipated receipt of systemic immunomodulatory agents or other immune&#xD;
             modifying drugs (including systemic corticosteroids exceeding 20 mg/day for ≥14 days)&#xD;
             and antineoplastic agents from up to six months prior to dosing and through the entire&#xD;
             duration of the study.&#xD;
&#xD;
          -  Planned medical procedure(s) that will impact study compliance during the follow-up&#xD;
             period.&#xD;
&#xD;
          -  Positive urine drug screen test or any evidence of ongoing drug abuse or dependence&#xD;
             (including alcohol), or recent history over the past five years of treatment for&#xD;
             alcohol or drug abuse.&#xD;
&#xD;
          -  Planning to donate bone marrow, blood, and blood products from the time of screening&#xD;
             until 3 months after receiving the last dose.&#xD;
&#xD;
          -  Have a tattoo/scar/birthmark or any other skin condition affecting the deltoid area&#xD;
             that may interfere with injection site assessments.&#xD;
&#xD;
          -  History of H. pylori or iron deficiency.&#xD;
&#xD;
          -  An opinion of the PI (or designee) that it would not be in the best interest of the&#xD;
             subject to allow participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Ajiboye, MD</last_name>
    <role>Study Director</role>
    <affiliation>Emergent BioSolutions</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie Bell</last_name>
    <phone>(704) 293-3377</phone>
    <email>bellk@ebsi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dominic Stanley</last_name>
    <phone>14086731288</phone>
    <email>stanleyd@ebsi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Mollie Walker</last_name>
      <phone>+61 (0) 8 6382 5106</phone>
      <email>mwalker@linear.org.au</email>
    </contact>
    <investigator>
      <last_name>Peter Richmond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>universal</keyword>
  <keyword>universal influenza vaccine</keyword>
  <keyword>phase 1</keyword>
  <keyword>randomized</keyword>
  <keyword>double-blind</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

